


MRS2365 trisodium

Cat. No.:	HY-108656A
Molecular Formula:	C ₁₃ H ₁₆ N ₅ Na ₃ O ₉ P ₂ S
Molecular Weight:	549.28
Target:	P2Y Receptor; Arrestin
Pathway:	GPCR/G Protein
Storage:	Solution, -20°C, 2 years



BIOLOGICAL ACTIVITY

Description	MRS2365 trisodium is a potent and selective P2Y1 receptor (EC ₅₀ =0.4 nM)/[³⁵ S]GTPγS binding/β-arrestin 2 recruitment agonist. MRS2365 trisodium relieves mechanical allodynia and increases mechanical sensitivity ^{[1][2][3][4]} .								
IC₅₀ & Target	P2Y1 Receptor 0.4 nM (EC ₅₀)								
In Vitro	MRS2365 trisodium (1 μM or 3 μM; 2 min) weakens adenosine diphosphate (ADP)-induced platelet aggregation ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	MRS2365 trisodium (0.03-0.3 mg/kg; i.p.; single dose) significantly alleviates the mechanical allodynia in the male wistar rats neuropathy (Seltzer) model with dose-dependent manner ^[3] . MRS2365 trisodium (0.1-2 mg/kg; i.p.; single dose) increases the paw withdrawal threshold (PWT) in male wistar rats with neuropathic pain model ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Male Wistar rats with neuropathic pain (250-350 g)^[3].</td> </tr> <tr> <td>Dosage:</td> <td>0.03, 0.1, 0.3, 1 and 2 mg/kg.</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; single dose.</td> </tr> <tr> <td>Result:</td> <td>Relieved mechanical allodynia and increased the paw withdrawal threshold.</td> </tr> </table>	Animal Model:	Male Wistar rats with neuropathic pain (250-350 g) ^[3] .	Dosage:	0.03, 0.1, 0.3, 1 and 2 mg/kg.	Administration:	Intraperitoneal injection; single dose.	Result:	Relieved mechanical allodynia and increased the paw withdrawal threshold.
Animal Model:	Male Wistar rats with neuropathic pain (250-350 g) ^[3] .								
Dosage:	0.03, 0.1, 0.3, 1 and 2 mg/kg.								
Administration:	Intraperitoneal injection; single dose.								
Result:	Relieved mechanical allodynia and increased the paw withdrawal threshold.								

REFERENCES

- [1]. Mariya Chhatriwala, et al. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. *J Pharmacol Exp Ther.* 2004 Dec;311(3):1038-43.
- [2]. D M Bourdon, et al. (N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets. *J Thromb Haemost.* 2006 Apr;4(4):861-8.
- [3]. Andó RD, et al. A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. *Br J Pharmacol.* 2010 Mar;159(5):1106-17.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA